Double SMCHD1 Variants in FSHD2: the Synergistic Effect of Two SMCHD1 Variants on D4Z4 Hypomethylation and Disease Penetrance in FSHD2
Total Page:16
File Type:pdf, Size:1020Kb
European Journal of Human Genetics (2016) 24, 78–85 & 2016 Macmillan Publishers Limited All rights reserved 1018-4813/16 www.nature.com/ejhg ARTICLE Double SMCHD1 variants in FSHD2: the synergistic effect of two SMCHD1 variants on D4Z4 hypomethylation and disease penetrance in FSHD2 Marlinde L van den Boogaard1, Richard JFL Lemmers1, Pilar Camaño2, Patrick J van der Vliet1, Nicol Voermans3, Baziel GM van Engelen3, Adolfo Lopez de Munain2, Stephen J Tapscott4, Nienke van der Stoep5, Rabi Tawil6 and Silvère M van der Maarel*,1 Facioscapulohumeral muscular dystrophy (FSHD) predominantly affects the muscles in the face, trunk and upper extremities and is marked by large clinical variability in disease onset and progression. FSHD is associated with partial chromatin relaxation of the D4Z4 repeat array on chromosome 4 and the somatic expression of the D4Z4 encoded DUX4 gene. The most common form, FSHD1, is caused by a contraction of the D4Z4 repeat array on chromosome 4 to a size of 1–10 units. FSHD2, the less common form of FSHD, is most often caused by heterozygous variants in the chromatin modifier SMCHD1, which is involved in the maintenance of D4Z4 methylation. We identified three families in which the proband carries two potentially damaging SMCHD1 variants. We investigated whether these variants were located in cis or in trans and determined their functional consequences by detailed clinical information and D4Z4 methylation studies. In the first family, both variants in trans were shown to act synergistically on D4Z4 hypomethylation and disease penetrance, in the second family both SMCHD1 function- affecting variants were located in cis while in the third family one of the two variants did not affect function. This study demonstrates that having two SMCHD1 missense variants that affect function is compatible with life in males and females, which is remarkable considering its role in X inactivation in mice. The study also highlights the variability in SMCHD1 variants underlying FSHD2 and the predictive value of D4Z4 methylation analysis in determining the functional consequences of SMCHD1 variants of unknown significance. European Journal of Human Genetics (2016) 24, 78–85; doi:10.1038/ejhg.2015.55; published online 18 March 2015 INTRODUCTION facilitates the production of stable DUX4 mRNA due to the presence Facioscapulohumeral muscular dystrophy (FSHD; OMIM 158900) is a of a polymorphic DUX4 polyadenylation signal distal to the D4Z4 common myopathy in adults, with a recently reported prevalence of repeat array.8,13 D4Z4 chromatin relaxation on non-permissive ~ 1:8000.1 FSHD is clinically characterized by weakness of the facial, chromosomes lacking a DUX4 polyadenylation signal do not cause shoulder girdle, trunk and upper arm muscles, which can be FSHD in the absence of detectable levels of DUX4 mRNA.8,14 asymmetric, and progresses to involve humeral, anterior lower leg Autosomal dominant FSHD1 is the most common form of FSHD muscles and pelvic girdle muscles.2 The onset of the disease is typically (495%), in which D4Z4 chromatin relaxation and DUX4 expression in the second decade of life, but the disease progression and severity are caused by a contraction of the D4Z4 repeat array to a size of 1–10 are highly variable.3 units.15,16 In the uncommon form of FSHD (FSHD2), D4Z4 The genetic forms identified thus far, FSHD1 and FSHD2, are chromatin relaxation occurs in the absence of D4Z4 repeat array clinically indistinguishable.4 Both forms are associated with partial contraction.5 In FSHD1, chromatin relaxation and CpG hypomethyla- chromatin relaxation of the D4Z4 macrosatellite repeat array on the tion are restricted to the contracted allele, whereas in FSHD2 subtelomere of the long arm of chromosome 4 and transcriptional chromatin relaxation and CpG hypomethylation occur at the D4Z4 derepression of the D4Z4 unit-encoded DUX4 retrogene in skeletal repeat arrays of both copies of chromosome 4 and in the highly muscle.5–9 DUX4 is a germ line transcription factor that is normally homologous repeat arrays on chromosome 10.4,9 repressed in somatic cells.7 Its expression in skeletal muscle activates Heterozygous variants in the structural maintenance of chromosomes genes involved in germ line and early stem cell development, as well as flexible hinge domain containing 1 (SMCHD1) gene on chromosome 18 specific classes of repeat elements, and overexpression of DUX4 in account for the majority of FSHD2 cases.14 SMCHD1 is an atypical somatic cells causes cell death.10–12 member of the SMC gene superfamily, a family of proteins which is To cause FSHD, D4Z4 chromatin relaxation must occur on a involved in chromosome condensation and cohesion, genome main- specific genetic background of chromosome 4 (most often 4A161) that tenance and gene regulation.17–19 Chromatin immunoprecipitation 1Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands; 2Neurosciences, BioDonostia Health Research Institute, Hospital Donostia, San Sebastián, Spain; 3Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands; 4Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 5Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; 6Department of Neurology, University of Rochester Medical Center, Rochester, MN, USA *Correspondence: Professor SM van der Maarel, Department of Human Genetics, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, The Netherlands. Tel: +31 715269481; Fax: +31 715268285; E-mail: [email protected] Received 30 October 2014; revised 17 February 2015; accepted 20 February 2015; published online 18 March 2015 Double SMCHD1 variants in FSHD2 ML van den Boogaard et al 79 studies showed the presence of SMCHD1 on the D4Z4 array and its For D4Z4 methylation analysis genomic DNA was double digested with reduced binding to D4Z4 in SMCHD1 mutation carriers.14 SMCHD1 EcoRI (Thermo Fisher Scientific Inc., Waltham, MA, USA) and BglII variants can also modify the disease severity in FSHD1 families, (Fermentas, Thermo Fisher Scientific) overnight at 37 °C, and cleaved DNA explaining some of the clinical variability seen in FSHD.20 was purified using PCR extraction columns (NucleoSpin Gel and PCR Clean- fi As a measure of D4Z4 chromatin relaxation, often D4Z4 methylation up, Machery-Nagel/BIOKÉ, Leiden, The Netherlands). Puri ed DNA was then ≥ is used. We have established a reliable and informative measure of digested with FseI (New England Biolabs/BIOKÉ) for 4 h, separated by size on 0.8% agarose gels, transferred to a nylon membrane (Hybond XL, D4Z4 methylation by measuring the methylation of all D4Z4 arrays Amersham, GE Healthcare, Diegem, Belgium) by Southern blotting and probed simultaneously at a unique methylation-sensitive restriction site (FseI) using the p13E-11 32P-labeled probe. Probe signals were quantified using 14 fi in the D4Z4 unit. The methylation level at this site is signi cantly the Storm 820 Phosphorimager (Amersham) and ImageQuant TL software lower in FSHD2 compared with both FSHD1 and controls, and a (Amersham). The signal from the 4061-bp fragment (methylated) was divided threshold of 25% was established for FSHD2.14 Recently, we showed by the total amount of hybridizing fragments at 4061 bp and 3387 bp that D4Z4 methylation level at this site is repeat array size (unmethylated) to yield the average percentage of methylated FseI sites within dependent.21 We introduced a new methylation parameter, Delta1, the most proximal D4Z4 unit on all four D4Z4 arrays. The Delta1 and Delta2 which represents the difference between the experimentally observed scores were calculated as described in Lemmars et al.21 methylation and the predicted methylation level based on repeat size in controls. In SMCHD1 mutation carriers, the average Delta1 score is SMCHD1 variant analysis highly negative ranging between − 20 and − 45, suggesting a strong For the index cases, SMCHD1 variant analysis was performed by Sanger fi contribution of the variant to D4Z4 hypomethylation.21 Accordingly, a sequencing after PCR ampli cation of all coding exons using intronic primers second model was then fitted to predict the methylation in SMCHD1 at a position of at least 50 nucleotides from the splice donor or acceptor site. The SMCHD1 genomic sequence was obtained from Ensemble (build 37) variant carriers, which resulted in the Delta2 score. For SMCHD1 (GRCh37:18:2655286:2805615) (Genomic Refseq: NG_031972.1, Transcript variants that preserve the open-reading frame (ORF), a mean Delta2 Refseq: NM_015295.2). Exons were numbered like in NG_031972.1 and − fi score of 1.8% was found, which is signi cantly lower than the mean primers were published previously.21 The functional consequences of variants Delta2 of ORF-disrupting variants (mean 2.7%). This suggests that were predicted using Alamut Visual version 2.4 (Interactive Biosoftware, ORF-preserving variants are more deleterious for the maintenance of a Rouen, France). Identified variants are submitted to the Leiden Open Variation repressed D4Z4 chromatin state in somatic cells.21 Database (http://databases.lovd.nl/shared/individuals/SMCHD1: submission Several studies have so far identified disease-causing variants in IDs 00028967–00028973) SMCHD1 in approximately 70 FSHD2 families. Heterozygous disease- For individual 385–203, Sanger sequencing of exons 24 and 45 in relatives causing SMCHD1 variants are distributed over the entire SMCHD1 was used to identify whether the two SMCHD1 variants